CERC-501

DRUG4 trials

Sponsors

Massachusetts General Hospital, Duke University, Janssen Research & Development, LLC, Yale University

Conditions

ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)SmokingTreatment Resistant Depression

Phase 2

Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

TerminatedNCT01913535

Massachusetts General HospitalTreatment Resistant Depression

Start: 2013-09-12End: 2016-01-22Updated: 2017-07-02

Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a

CompletedNCT02218736

Duke UniversityANXIETY DISORDERS (or Anxiety and Phobic Neuroses)

Start: 2015-06-30End: 2017-12-01Updated: 2019-01-08

A Study in a Human Laboratory Model of Smoking Behavior

CompletedNCT02641028

Janssen Research & Development, LLCSmoking

Start: 2015-12-31End: 2016-12-31Updated: 2025-04-27

Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?

CompletedNCT02800928

Yale UniversitySmoking

Start: 2016-06-30End: 2018-01-02Updated: 2019-08-13